Subscribe To
TYRA / Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
TYRA News
By Zacks Investment Research
June 7, 2023
Wall Street Analysts Think Tyra Biosciences, Inc. (TYRA) Could Surge 52.22%: Read This Before Placing a Bet
The consensus price target hints at a 52.2% upside potential for Tyra Biosciences, Inc. (TYRA). While empirical research shows that this sought-after more_horizontal
By Seeking Alpha
June 1, 2023
Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules
TYRA has the first FGFR3 inhibitor in the clinic. The company has a large market cap for an early-stage company and a good deal of cash. They do not h more_horizontal
By Zacks Investment Research
May 23, 2023
What Makes Tyra Biosciences, Inc. (TYRA) a Good Fit for 'Trend Investing'
Tyra Biosciences, Inc. (TYRA) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit fr more_horizontal
By Zacks Investment Research
March 27, 2023
Here's Why 'Trend' Investors Would Love Betting on Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on th more_horizontal
By Zacks Investment Research
March 1, 2023
Should You Buy Tyra Biosciences (TYRA) Ahead of Earnings?
Tyra Biosciences (TYRA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal
By PRNewsWire
September 8, 2022
Tyra Biosciences to Participate at September 2022 Investor Conferences
CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-bui more_horizontal
By PRNewsWire
September 5, 2022
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-bui more_horizontal